KYUNG NAM PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,044 KRW | -.--% |
|
-7.45% | -37.93% |
| 2023 | Kyung Nam Pharm Co.,Ltd. announced that it has received KRW 5 billion in funding | CI |
| 2023 | Kyung Nam Pharm Co.,Ltd. announced that it expects to receive KRW 5 billion in funding | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 211,555 | 169,679 | 140,585 | 88,518 | 82,676 | 59,868 |
| Enterprise Value (EV) 1 | 217,740 | 146,784 | 154,482 | 104,785 | 70,391 | 76,185 |
| P/E ratio | 52.6 x | -34 x | -25.3 x | -10.7 x | -11.5 x | -2.84 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 5.11 x | 3.79 x | 1.98 x | 1.37 x | 1.4 x | 0.87 x |
| EV / Revenue | 5.26 x | 3.28 x | 2.18 x | 1.62 x | 1.19 x | 1.11 x |
| EV / EBITDA | -319 x | -66.4 x | 41.2 x | -15.1 x | -48.5 x | -19.8 x |
| EV / FCF | -14.9 x | -31.9 x | -4.98 x | -4.81 x | -24.6 x | -6.82 x |
| FCF Yield | -6.71% | -3.14% | -20.1% | -20.8% | -4.06% | -14.7% |
| Price to Book | 7.32 x | 2.77 x | 2.45 x | 1.22 x | 0.9 x | 0.75 x |
| Nbr of stocks (in thousands) | 12,300 | 17,053 | 17,442 | 20,049 | 30,849 | 35,593 |
| Reference price 2 | 17,200 | 9,950 | 8,060 | 4,415 | 2,680 | 1,682 |
| Announcement Date | 28/03/19 | 17/03/20 | 18/03/21 | 17/03/22 | 15/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 41,433 | 44,806 | 70,947 | 64,623 | 59,000 | 68,445 |
| EBITDA 1 | -683.3 | -2,212 | 3,751 | -6,925 | -1,450 | -3,854 |
| EBIT 1 | -1,391 | -3,332 | 2,225 | -8,756 | -3,411 | -6,712 |
| Operating Margin | -3.36% | -7.44% | 3.14% | -13.55% | -5.78% | -9.81% |
| Earnings before Tax (EBT) 1 | 6,316 | -6,208 | -7,492 | -3,299 | -7,395 | -21,059 |
| Net income 1 | 3,720 | -4,546 | -5,488 | -3,413 | -6,779 | -20,997 |
| Net margin | 8.98% | -10.15% | -7.73% | -5.28% | -11.49% | -30.68% |
| EPS 2 | 326.7 | -293.0 | -318.2 | -413.0 | -232.3 | -593.0 |
| Free Cash Flow 1 | -14,617 | -4,605 | -31,033 | -21,802 | -2,860 | -11,174 |
| FCF margin | -35.28% | -10.28% | -43.74% | -33.74% | -4.85% | -16.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 28/03/19 | 17/03/20 | 18/03/21 | 17/03/22 | 15/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 6,185 | - | 13,898 | 16,268 | - | 16,318 |
| Net Cash position 1 | - | 22,895 | - | - | 12,285 | - |
| Leverage (Debt/EBITDA) | -9.052 x | - | 3.705 x | -2.349 x | - | -4.234 x |
| Free Cash Flow 1 | -14,617 | -4,605 | -31,033 | -21,802 | -2,860 | -11,174 |
| ROE (net income / shareholders' equity) | 16.8% | -10.1% | -9.26% | -4.94% | -7.88% | -24.2% |
| ROA (Net income/ Total Assets) | -1.63% | -3.26% | 1.38% | -4.34% | -1.58% | -2.75% |
| Assets 1 | -228,739 | 139,304 | -396,793 | 78,576 | 428,424 | 762,953 |
| Book Value Per Share 2 | 2,351 | 3,588 | 3,289 | 3,618 | 2,976 | 2,230 |
| Cash Flow per Share 2 | 684.0 | 1,404 | 1,303 | 1,144 | 1,284 | 729.0 |
| Capex 1 | 527 | 1,323 | 45,582 | 2,306 | 2,851 | 16,823 |
| Capex / Sales | 1.27% | 2.95% | 64.25% | 3.57% | 4.83% | 24.58% |
| Announcement Date | 28/03/19 | 17/03/20 | 18/03/21 | 17/03/22 | 15/03/23 | 20/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -37.93% | 26.87M | |
| +15.91% | 41.97B | |
| +22.40% | 22.34B | |
| +18.48% | 15.25B | |
| +16.12% | 14B | |
| +45.12% | 12.06B | |
| -9.58% | 6.8B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +14.18% | 5.49B |
- Stock Market
- Equities
- A053950 Stock
- Financials Kyung Nam Pharm Co.,Ltd.
